Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- selexipag
- Voydeya (danicopan)
Interactions between your drugs
selexipag danicopan
Applies to: selexipag, Voydeya (danicopan)
MONITOR: Coadministration with danicopan may increase the plasma concentrations of drugs that are substrates of the efflux transporters breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp). The proposed mechanism involves decreased clearance due to inhibition of BCRP and P-gp by danicopan. In clinical drug interaction studies, when subjects were coadministered the BCRP substrate rosuvastatin (single 20 mg dose) with danicopan at steady state (200 mg three times daily for 4 days), the peak plasma concentration (Cmax) and systemic exposure (AUC) of rosuvastatin increased by 3.3-fold and 2.2-fold, respectively. In addition, when the P-gp substrate fexofenadine (single 180 mg dose) was coadministered with danicopan (150 mg three times daily for 4 days), the peak plasma concentration (Cmax) and systemic exposure (AUC) of fexofenadine increased by 1.4-fold and 1.6-fold, respectively. Similarly, when subjects were coadministered the P-gp substrate tacrolimus (single 2 mg dose) with danicopan (200 mg three times daily for 5 days), the Cmax and AUC of tacrolimus increased by 1.1-fold and 1.5-fold, respectively.
MANAGEMENT: Caution and clinical monitoring are recommended if danicopan is coadministered with drugs that are substrates of the transporters BCRP and/or P-gp, particularly sensitive substrates, or those with a narrow therapeutic range. Dosage adjustments as well as closer clinical and laboratory monitoring for the development of adverse effects may be appropriate for some drugs whenever danicopan is added to or withdrawn from therapy. Individual product labeling should be consulted for further guidance.
References (3)
- (2024) "Product Information. Voydeya (danicopan)." Alexion Pharmaceuticals Inc
- (2024) "Product Information. Voydeya (danicopan)." Alexion Pharmaceuticals Australasia Pty Ltd, CCDS v5.0
- (2024) "Product Information. Voydeya (danicopan)." Alexion Pharma Canada Corp.
Drug and food interactions
selexipag food
Applies to: selexipag
Food prolongs the gastrointestinal absorption of selexipag. When taken with food, the time to peak concentration (Tmax) was delayed and peak plasma concentration (Cmax) was approximately 30% lower. Selexipag systemic exposure (AUC) and that of its active metabolite did not significantly change, however. Selexipag may be taken with or without food. Tolerability may be improved when taken with food.
References (1)
- (2016) "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cialis
Cialis (tadalafil) increase increases blood flow to a certain area of the body and is used to treat ...
Viagra
Viagra (sildenafil) is used to treat erectile dysfunction or impotence in men. Includes Viagra side ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Adcirca
Adcirca is used to treat pulmonary arterial hypertension. Learn about side effects, interactions ...
Opsumit
Opsumit (macitentan) is used to treat pulmonary arterial hypertension. Includes Opsumit side ...
Revatio
Revatio (sildenafil) is used to treat pulmonary arterial hypertension. Includes Revatio side ...
Adempas
Adempas (riociguat) is used to treat pulmonary hypertension. Includes Adempas side effects ...
Winrevair
Winrevair (sotatercept) is an injectable activin signaling inhibitor that can be self-administered ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.